By Scientia Professor Vlado Perkovic

Journal articles

Levin A; Cherney D; Wheeler DC; Gogate J; Haynes M; Perkovic V, 2021, 'Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE', Journal of the American Society of Nephrology, 32, pp. 263 - 264, http://dx.doi.org/10.1681/asn.20213210s1263b

Pergola PE; Davidson M; Devalaraja M; Ivkovic M; Johansen NJ; Raj DS; Sode BF; Tuttle KR; Perkovic V, 2021, 'IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis', Journal of the American Society of Nephrology, 32, pp. 190 - 190, http://dx.doi.org/10.1681/asn.20213210s1190c

Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Makino H; McMurray J; Perkovic V; Tobe SW; Parving H-H; de Zeeuw D; Heerspink HJL, 2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Trial', Journal of the American Society of Nephrology, 32, pp. 728 - 728, http://dx.doi.org/10.1681/asn.20213210s1728b

Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V, 2020, 'Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m²: Subgroup analysis of the randomized CREDENCE trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1705 - 1714, http://dx.doi.org/10.2215/CJN.10140620

Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX, 2020, 'Higher-dose sitagliptin and the risk of congestive heart failure in older adults with CKD', Clinical Journal of the American Society of Nephrology, 15, pp. 1728 - 1739, http://dx.doi.org/10.2215/CJN.08310520

Oshima M; Neuen BL; Li JW; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; de Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL, 2020, 'Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial', Journal of the American Society of Nephrology, 31, pp. 2925 - 2936, http://dx.doi.org/10.1681/ASN.2020050723

Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM; Wyndham R; Vilayur E; Cooper B; Wong MG; Tan KS; van Eps C; Cho Y; Barbara J; Paizis K; McMahon LP; Nelson C; Gafor AHA; Meng OL; Mushahar L; Maher E, 2020, 'A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)', Journal of the American Society of Nephrology, 31, pp. 2653 - 2666, http://dx.doi.org/10.1681/ASN.2020040411

Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL, 2020, 'Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial', The Lancet Diabetes and Endocrinology, 8, pp. 903 - 914, http://dx.doi.org/10.1016/s2213-8587(20)30300-4

Matthews DR; Wysham C; Davies M; Slee A; Alba M; Lee M; Perkovic V; Mahaffey KW; Neal B, 2020, 'Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 2199 - 2203, http://dx.doi.org/10.1111/dom.14143

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; de Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning', Journal of Cardiac Failure, 26, pp. 1028 - 1029, http://dx.doi.org/10.1016/j.cardfail.2020.09.001

Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B, 2020, 'The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program', International Journal of Cardiology, 318, pp. 126 - 129, http://dx.doi.org/10.1016/j.ijcard.2020.06.011

Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V, 2020, 'Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program', Journal of the American Society of Nephrology, 31, pp. 2446 - 2456, http://dx.doi.org/10.1681/ASN.2019121312

Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C, 2020, 'Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: Post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1433 - 1444, http://dx.doi.org/10.2215/CJN.14901219

Levin A; Agarwal R; Herrington WG; Heerspink HL; Mann JFE; Shahinfar S; Tuttle KR; Donner JA; Jha V; Nangaku M; de Zeeuw D; Jardine MJ; Mahaffey KW; Thompson AM; Beaucage M; Chong K; Roberts GV; Sunwold D; Vorster H; Warren M; Damster S; Malik C; Perkovic V; Anand S; Argent N; Babak E; Banerjee D; Barratt J; Bello AK; Bernardo AA; Blais J; Canovatchel W; Caskey FJ; Coresh J; de Boer IH; Eckardt KU; Evans RD; Feldman HI; Fogo AB; Gudmundsdottir H; Hamano T; Harris DCH; Hauske SJ; Haynes R; Herzog CA; Hiemstra T; Idorn T; Inker L; Ishida JH; Johnson DW; Jones-Burton C; Joseph A; Koitka-Weber A; Kretzler M; Lawatscheck R; Liew A; Moist L; Naicker S; Nakashima R; Patel U; Filho RP; Rose JB; Rosenberg NL; Sinsakul M; Smoyer WE; Sola L; Sood AR; Stengel B; Taal MW; Tanaka M; Tonelli M; Tong A; Toto R; Trask M; Ulasi II; Wanner C; Wheeler DC; Wolthers BO; Wright HM; Yamada Y; Zakharova E, 2020, 'International consensus definitions of clinical trial outcomes for kidney failure: 2020', Kidney International, 98, pp. 849 - 859, http://dx.doi.org/10.1016/j.kint.2020.07.013

Smyth B; Zuo L; Gray NA; Chan CT; de Zoysa JR; Hong D; Rogers K; Wang J; Cass A; Gallagher M; Perkovic V; Jardine M, 2020, 'No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial', Nephrology, 25, pp. 792 - 800, http://dx.doi.org/10.1111/nep.13737

Torda AJ; Velan G; Perkovic V, 2020, 'The impact of the COVID-19 pandemic on medical education', Medical Journal of Australia, 213, pp. 334 - 334.e1, http://dx.doi.org/10.5694/mja2.50762

Zhu B; Jun M; Jardine MJ; Wang YJ; Perkovic V, 2020, 'Haemodialysis duration, frequency and intensity for end-stage kidney disease', Cochrane Database of Systematic Reviews, 2020, http://dx.doi.org/10.1002/14651858.CD010064.pub2

Li JW; Neal B; Perkovic V; de Zeeuw D; Neuen BL; Arnott C; Simpson R; Oh R; Mahaffey KW; Heerspink HJL, 2020, 'Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes', Kidney International, 98, pp. 769 - 777, http://dx.doi.org/10.1016/j.kint.2020.04.051

Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M, 2020, 'Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: A network meta-analysis of randomized, controlled trials', Clinical Journal of the American Society of Nephrology, 15, pp. 1129 - 1138, http://dx.doi.org/10.2215/CJN.12201019

Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; Eynatten MV; George JT; Johansen OE; Wanner C, 2020, 'Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: Secondary analysis of the carmelina randomized trial', Diabetes Care, 43, pp. 1803 - 1812, http://dx.doi.org/10.2337/dc20-0279

Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; De Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; Neal B, 2020, 'Effects of allopurinol on the progression of chronic kidney disease', New England Journal of Medicine, 382, pp. 2504 - 2513, http://dx.doi.org/10.1056/NEJMoa1915833

LI J; JARDINE MJ; NEAL B; HEERSPINK HL; CANNON C; AGARWAL R; BAKRIS G; CHARYTAN DM; ZEEUW DD; EDWARDS R; GREENE TOM; LEVIN A; POLLOCK CA; ROSENTHAL N; WHEELER DC; ZHANG H; ZINMAN B; PERKOVIC V; MAHAFFEY KW; ARNOTT C, 2020, '27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease', Diabetes, 69, http://dx.doi.org/10.2337/db20-27-or

Tuttle K; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa140.mo051

Kang A; Neuen B; Heerspink HL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M; Lambers Heerspink H, 2020, 'P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1013, http://dx.doi.org/10.1093/ndt/gfaa142.p1013

Kang A; Smyth B; Neuen B; Lambers Heerspink H; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M, 2020, 'P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa142.p1019

Young T; Li J-W; Kang A; Heerspink H; Hockham C; Arnott C; Neuen B; Zoungas S; Mahaffey KW; Perkovic V; De Zeeuw D; Fulcher G; Neal B; Jardine M, 2020, 'P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1028, http://dx.doi.org/10.1093/ndt/gfaa142.p1028

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; De Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis', Journal of Cardiac Failure, 26, pp. 482 - 491, http://dx.doi.org/10.1016/j.cardfail.2020.03.010

Tuttle K; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa141.to002

Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B, 2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, 22, pp. 1753 - 1766, http://dx.doi.org/10.1111/dom.14091

Torda A; Perkovic V; Velan G, 2020, 'The impact of COVID-19 pandemic on medical education', Medical Journal of Australia, 213, pp. 188 - 188.e1, http://dx.doi.org/10.5694/mja2.50705

Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; De Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V, 2020, 'Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial', Journal of the American Society of Nephrology, 31, pp. 1128 - 1139, http://dx.doi.org/10.1681/ASN.2019111168

Ohkuma T; Van Gaal L; Shaw W; Mahaffey KW; de Zeeuw D; Matthews DR; Perkovic V; Neal B, 2020, 'Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 530 - 539, http://dx.doi.org/10.1111/dom.13920

Inagaki N; Yang W; Watada H; Ji L; Schnaidt S; Pfarr E; Okamura T; Johansen OE; George JT; von Eynatten M; Rosenstock J; Perkovic V; Wanner C; Cooper ME; Alexander JH; Komuro I; Nangaku M, 2020, 'Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA^® trial', Diabetology International, 11, pp. 129 - 141, http://dx.doi.org/10.1007/s13340-019-00412-x

Cannon CP; Perkovic V; Agarwal R; Baldassarre J; Bakris G; Charytan DM; De Zeeuw D; Edwards R; Greene T; Heerspink HJL; Jardine MJ; Levin A; Li JW; Neal B; Pollock C; Wheeler DC; Zhang H; Zinman B; Mahaffey KW, 2020, 'Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial', Circulation, 141, pp. 407 - 410, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044359

Arnott C; Li Q; Kang A; Neuen BL; Bompoint S; Lam CSP; Rodgers A; Mahaffey KW; Cannon CP; Perkovic V; Jardine MJ; Neal B, 2020, 'Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis', Journal of the American Heart Association, 9, pp. e014908, http://dx.doi.org/10.1161/JAHA.119.014908

Li JW; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B, 2020, 'Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes', JACC: Heart Failure, 8, pp. 57 - 66, http://dx.doi.org/10.1016/j.jchf.2019.08.004

Neuen BL; Perkovic V, 2020, 'Pilot trials in nephrology: Establishing a base for large-scale randomized trials', Journal of the American Society of Nephrology, 31, pp. 4 - 6, http://dx.doi.org/10.1681/ASN.2019111196

Heerspink HJL; Oshima M; Jardine MJ; Agarwal R; Bakris GL; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; Neal B; Pollock CA; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Perkovic V, 2020, 'Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE', Journal of the American Society of Nephrology, 31, pp. 342 - 343, http://dx.doi.org/10.1681/asn.20203110s1342b

Sen T; Li J; Neuen BL; Parikh CR; Coca SG; Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Hansen MK; Heerspink HJL, 2020, 'Associations Between TNFR-1, TNFR-2, and KIM-1 with Kidney and Cardiovascular Outcomes: Results from the CANVAS Trial', Journal of the American Society of Nephrology, 31, pp. 338 - 338, http://dx.doi.org/10.1681/asn.20203110s1338c

Neuen BL; Yu J; Li Q; Perkovic V; Arnott CG; Neal B; Heerspink HJL; Agarwal R; Bakris GL; Cannon CP; de Zeeuw D; Charytan DM; Levin A; Di Tanna GL; Matthews DR; Pollock CA; Wheeler DC; Mahaffey KW; Jardine MJ, 2020, 'Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE', Journal of the American Society of Nephrology, 31, pp. b6 - b6, http://dx.doi.org/10.1681/asn.20203110s1b6a

Kang A; Neuen BL; Heerspink HJL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris GL; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock CA; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2020, 'Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343c

Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris GL; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock CA; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2020, 'Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344a

Rasmussen DGK; Jatkoe T; Sparding N; Mϕller AL; Karsdal MA; Rosenthal N; Gutstein DE; Neal B; Perkovic V; Mahaffey KW; Genovese F; Hansen MK, 2020, 'Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343b

Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock CA; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL, 2020, 'Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344b

Levin A; Neuen BL; Mahaffey KW; Cannon CP; Jardine MJ; Heerspink HJL; Neal B; Arnott CG; Zhou Z; Charytan DM; Agarwal R; Bakris GL; de Zeeuw D; Greene T; Wheeler DC; Rosenthal N; Zhang H; Zinman B; Perkovic V; Pollock CA, 2020, 'Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 342 - 342, http://dx.doi.org/10.1681/asn.20203110s1342a

Young TK; Li J; Kang A; Heerspink HJL; Hockham C; Arnott CG; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine MJ, 2020, 'Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344c

Tuttle KR; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials', Journal of the American Society of Nephrology, 31, pp. 349 - 350, http://dx.doi.org/10.1681/asn.20203110s1349c

Cherney D; Hadjadj S; Idorn T; Mosenzon O; Pilemann-Lyberg S; Perkovic V; Tuttle KR; Rasmussen S; Bain SC, 2020, 'Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs', Journal of the American Society of Nephrology, 31, pp. 349 - 349, http://dx.doi.org/10.1681/asn.20203110s1349b

Tuttle KR; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6', Journal of the American Society of Nephrology, 31, pp. 36 - 36, http://dx.doi.org/10.1681/asn.20203110s136a

Bakris GL; Jardine MJ; Zhou Z; Heerspink HJL; Li Q; Agarwal R; Charytan DM; Oh R; Pollock CA; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2020, 'Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis', Journal of the American Society of Nephrology, 31, pp. 328 - 328, http://dx.doi.org/10.1681/asn.20203110s1328a

Back to profile page